Articles related to CLINICAL TRIALS

The researchers believe these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, demonstrating comparable efficacy and manageable safety. Experimentation revealed that FGFR3 DNA alterations in conjunction with FGFR1/3 mRNA overexpression may be better predictors of rogaratinib response.

The use of thalidomide analogs, specifically lenalidomide, has been linked to an increased risk of TP53-mutated myeloid neoplasms. Furthermore, lenalidomide, but not pomalidomide, causes the expansion of preleukemic Trp53-mutant HSPCs via selective Ck1 degradation.

The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, shares insights from trial and how these key clinical findings could change obesity management.

To test whether low doses of the NMDA-receptor partial-agonist D-cycloserine would enhance intermittent TBS (iTBS) treatment outcomes in MDD, this single-site 4-week, double-blind, placebo-controlled, randomized clinical trial compared TBS with D-cycloserine vs. TBS with placebo. The TBS plus D-cycloserine group had greater improvements in MADRS scores compared with the iTBS plus placebo group, with a mean difference of −6.15.

The study, led by Michael Bretthauer, MD, PhD, of the University of Oslo in Norway, found that people who were invited to have a screening colonoscopy had a lower risk of colorectal cancer than those who were not, though at a lower rate than researchers expected. Furthermore, no significant difference in colorectal cancer-related mortality was discovered between the two groups.

The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can produce complete and long-lasting clinical responses as well as molecular remission in KIT D816V patients. The complex mutational landscape of AdvSM, which is frequently associated with a hematologic neoplasm, poses significant management challenges.